secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardio Diagnostics Holdings, Inc. (CDIO)
CIK:        0001870144
Form:       8-K
Filed at:   2026-08-20T12:03:24+00:00
Accession:  0001079973-26-001153
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CDIO investor deck: CMS $854/test rate set; Atlas coverage; Dr. Lal PathLabs India deal; lab scale-up
--------------------------------------------------------------------------------

- CMS final payment rate of $854 per test set (Dec 2025) for both Epi+Gen CHD (0439U) and PrecisionCHD (0440U) CPT codes.
- Atlas Healthcare Physicians began in-network coverage with prior authorization (June 2026); out-of-network billing launched July 2026.
- Dr. Lal PathLabs (290+ labs, 300+ pathologists) to offer PrecisionCHD in India; Aimil Ltd partnership extends distribution network.
- Company-owned CLIA lab now processing tests in-house, cutting initial COGS ~30%; turnaround time 7-10 business days.
- Combined US TAM ~$175B: 146M eligible for Epi+Gen CHD risk test, 60M for PrecisionCHD diagnostic; 40% gross margin target at scale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870144/000107997326001153/0001079973-26-001153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870144/000107997326001153/cdio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001079973-26-001153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer